论文部分内容阅读
目的:比较奥先达联合紫杉醇或卡铂联合紫杉醇治疗卵巢上皮癌的疗效和安全性。方法:2010年8月到2012年4月入组了Ⅱ期以上行满意的肿瘤细胞减灭术的卵巢上皮癌患者182例。术后将患者随机分为奥先达组(92例)和卡铂组(90例),分别采用奥先达或卡铂联合紫杉醇方案治疗。奥先达剂量80mg/m2,或卡铂AUC=5,第2天给药;紫杉醇135mg/m2,第1天给药,21天1个疗程。研究两组患者治疗的近期疗效和药物安全性。结果:奥先达组、卡铂组患者完成的治疗周期数分别为5.02±1.63和5.39±1.30。奥先达组化疗第3、6个周期结束时,CA125下降到正常水平的比率分别为80.00%和86.36%,卡铂组为72.88%和86.00%,两组比较均无统计学差异;治疗后两组患者的KPS、QOL评分均明显改善,但两组间比较无统计学差异。奥先达组恶心呕吐发生率为3.26%,卡铂组为5.56%;奥先达组和卡铂的Ⅲ～Ⅳ度白细胞减少的发生率分别为10.87%和23.33%,两组差异有统计学意义(P<0.05);两组的其他毒性反应发生率无统计学差异(P>0.05)。结论:奥先达联合紫杉醇治疗卵巢上皮癌近期疗效与卡铂方案相似,但其毒副反应较轻,患者耐受性好。
OBJECTIVE: To compare the efficacy and safety of oxassine plus paclitaxel or carboplatin plus paclitaxel in the treatment of epithelial ovarian cancer. Methods: From August 2010 to April 2012, 182 patients with epithelial ovarian cancer who underwent satisfactory cytoreductive surgery at stage Ⅱ were enrolled. Patients were randomly divided into the Aoxeda group (n = 92) and the carboplatin group (n = 90). The patients were treated with Auxeda or carboplatin in combination with paclitaxel. Aoxinda dose 80mg / m2, or carboplatin AUC = 5, the second day of administration; paclitaxel 135mg / m2, the first day of administration, 21 days a course of treatment. To study the short-term efficacy of the two groups of patients and drug safety. Results: The number of treatment cycles completed by the patients in the COX group and carboplatin group were 5.02 ± 1.63 and 5.39 ± 1.30, respectively. At the end of the 3rd and 6th cycles of oxmax group, the rates of CA125 down to normal were 80.00% and 86.36% respectively, while those in carboplatin group were 72.88% and 86.00% respectively. There was no significant difference between the two groups after treatment KPS and QOL scores of both groups were significantly improved, but there was no significant difference between the two groups. The incidence of nausea and vomiting was 3.26% in the Aoxida group and 5.56% in the carboplatin group. The incidences of Ⅲ ~ Ⅳ leukopenia in the Aoxeda group and carboplatin were 10.87% and 23.33% respectively, with statistical differences between the two groups (P <0.05). There was no significant difference in the incidence of other toxic reactions between the two groups (P> 0.05). CONCLUSION: The efficacy of oxdantol plus paclitaxel in the treatment of epithelial ovarian cancer is similar to that of carboplatin, but its side effects are mild and the patients are well tolerated.